What Диклофенак буфус Treats: Main Uses and Benefits

The injectable form of this medication is relevant across therapeutic domains where short-term symptomatic assistance is needed, applied in clinical settings that involve acute or unstable symptom patterns. It is commonly used across conditions presenting with acute episodes. The primary clinical scenarios include managing exacerbations of rheumatic conditions like osteoarthritis and rheumatoid arthritis, addressing crisis-level pain episodes such as renal colic (kidney stone pain), and is applied in addressing discomfort and swelling following acute physical trauma or surgical procedures.

It is applied in addressing symptom clusters that become more disruptive during flare-ups and provides supportive relief when symptoms create noticeable physiological strain. It contributes to easing the overall symptom load during acute phases, which may assist with maintaining functional stability.

“The medication is used in situations involving distressing symptoms related to inflammatory states, which helps patients cope more steadily.”

Quick Fact: Relevant for Acute Inflammatory Pain and Crisis Episodes

Regulatory References

1. Official Drug Information from the Philippine FDA

Eligibility Map: Who Can and Cannot Use Diclofenac

Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) whose use is governed by official restrictions, primarily due to risks affecting the cardiovascular and gastrointestinal systems.

Eligibility Classification	Populations/Conditions
FORMALLY CONTRAINDICATED	Active gastric or intestinal ulceration, bleeding, or perforation. Hypersensitivity to diclofenac, acetylsalicylic acid, or other NSAIDs (e.g., NSAID-induced asthma/urticaria). Severe hepatic or renal failure. Established cardiovascular diseases: Ischemic Heart Disease, Peripheral Arterial Disease, Cerebrovascular Disease, or Congestive Heart Failure (NYHA class II-IV). Third Trimester of Pregnancy. Use for perioperative pain in Coronary Artery Bypass Graft (CABG) surgery.
USE REQUIRES CAUTION / NOT RECOMMENDED	Patients with significant cardiovascular risk factors (e.g., hypertension, diabetes, hyperlipidaemia, smoking). Elderly patients. First and Second Trimesters of Pregnancy (use only if clearly necessary). Patients with impaired hepatic or renal function, or history of gastrointestinal disease (e.g., ulcerative colitis, Crohn's disease).
AGE-RELATED RULES	Generally not recommended for children 14 years of age or below (due to dosage strength or formulation restrictions). Elderly patients require caution and often the lowest effective dose.

The regulatory profile for diclofenac is strictly defined by major contraindications in patients with severe cardiac conditions and active gastrointestinal bleeding or ulceration. Use is further limited, requiring careful professional consideration in individuals with cardiovascular risk factors and in specific physiological states like pregnancy and advanced age.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Diclofenac (as an NSAID) based on two principal concerns: additive adverse risk and pharmacokinetic exposure modification. Certain combinations are formally restricted or contraindicated due to the documented potential for severe outcomes.

Documented Pharmacodynamic and Contraindicated Interactions

Interaction Classification	Interacting Agents and Regulatory Restriction
Additive Pharmacodynamic Risk	Co-administration with other systemic NSAIDs or high-dose Aspirin is restricted due to a heightened risk of serious gastrointestinal adverse events, including bleeding and ulceration. This risk is also significantly increased when combined with Corticosteroids or certain Anticoagulants (e.g., Warfarin).
Perioperative Contraindication	Diclofenac is formally restricted from treating pain related to Coronary Artery Bypass Graft (CABG) surgery.

---

Exposure Modification and Drug Clearance Interference

The co-administration of Diclofenac with certain medicines requires specific regulatory consideration:

• CYP2C9 Inhibitors: Strong inhibitors of the CYP2C9 enzyme, such as Voriconazole, are documented to cause a significant increase in Diclofenac plasma concentration and exposure.
• Renal Clearance: Diclofenac may interfere with the renal clearance of substances like Lithium and Methotrexate, which is documented to increase their plasma levels and risk of toxicity.
• Antihypertensives and Diuretics: Co-administration may diminish the therapeutic effect of these agents while increasing the official risk of renal impairment.

Other Documented Substance Interactions

Consumption of alcohol is documented to increase the risk of serious gastrointestinal adverse events. Herbal products such as Ginkgo biloba are noted in official sources as potentially increasing the risk of bleeding.

How Диклофенак Буфус Works: Mechanism of Action

Core Action: Enzyme Inhibition and Prostanoid Synthesis

The primary mechanism of Диклофенак буфус involves competitive inhibition of the Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This enzyme blockade stops the metabolism of arachidonic acid into prostanoids like PGE2 and thromboxanes. This domain involves the fundamental molecular cascade for generating key mediators of inflammation and nociception.

Systemic Modulation of Inflammation and Nociception

By reducing the synthesis of prostaglandins, the drug exerts its physiological effects by limiting inflammatory responses and decreasing peripheral pain signaling (nociception). Fewer prostaglandins result in reduced local vasodilation, decreased edema, and diminished sensitization of peripheral nerve endings. This system-wide suppression of overactive chemical signaling results in the physiological outcomes of limited inflammatory response and decreased peripheral nociception.

Regulation of Thermoregulation and Pain Transmission

A specific downstream effect of prostaglandin reduction is the modulation of the body’s thermoregulatory center in the hypothalamus. Furthermore, the drug influences other pain-relevant systems, including ion channels and the neuropeptide Substance P, contributing to the resultant antinociception. This mechanism acts to stabilize hyper-reactive physiological processes. The dual action modulates both the eicosanoid synthesis and the peripheral signal transmission, which shapes the resulting physiological effect profile.

This information describes the official administration of Diclofenac (as Диклофенак буфус) solution for injection, intended for adult patients and short-term use.

Administration Overview

Classification	Rule
Route of Administration	Deep intramuscular (IM) injection.
Standard Single Dose	75 mg (one ampoule).
Maximum Daily Dose	150 mg (total from all diclofenac forms).
Use Duration	Not more than two days (initial therapy).

Procedural Steps and Dosing Rules

1. Preparation Check: Only use the solution if it is transparent and free of any particulate matter or crystallization. The ampoule is for single use only.
2. Injection Technique: The injection must be administered slowly and deeply into the upper outer quadrant of the gluteal muscle (buttock) using an aseptic technique to minimize local tissue damage and potential nerve complications.
3. Frequency and Interval: The standard dose is 75 mg once daily. In severe or exceptional cases (e.g., renal colic), a second 75 mg dose may be given. This second injection should be administered into the opposite buttock and no earlier than 6 to 12 hours after the first dose, depending on the specific regimen.
4. Dose Limit: The total dose of diclofenac from all dosage forms (injection, oral tablets, suppositories) must not exceed 150 mg within any 24-hour period (except for an absolute maximum of 175 mg on the first day in specific scenarios like migraine attacks).
5. Transition: This injectable form is generally intended for short-term use only (maximum of 1–2 days) and treatment should be continued with oral or rectal diclofenac forms thereafter, if required.

This procedural structure details the established technical and dose-limiting steps for the adult intramuscular administration of the drug, emphasizing deep injection technique and strict adherence to the maximum total daily dose to avoid exceeding safe therapeutic levels.

Research evidence / Overview of studies

---

Overview of Core Research

Research has explored the study objectives related to recovery time and changes in self-reported measures of pain and mobility in study participants with inflammatory and painful conditions. Studies were designed to evaluate the hypothesis that the compound may affect inflammatory markers, and whether changes in these markers relate to the frequency of reported flare-ups over the study period. Trials also included an assessment of the tolerability profile. Individuals with certain pre-existing conditions were often excluded from trials or had specific monitoring protocols.

---

Key Study Findings

Phase 3: Monotherapy Trials

Preliminary trials provided initial data on participant responses and tolerability. Research compared the effects of the compound against a comparator group (e.g., a traditional therapy or placebo) on various outcome measures. Studies explored whether the compound was associated with changes in the frequency of reported symptoms and self-reported well-being over the trial duration.

Assessment Area	Primary Trial Focus
Primary Endpoint	To assess whether participants receiving the compound showed a difference in the primary outcome measure compared to the placebo group.
Dosing	Clinical trials utilized various dosing schedules, with some studies focusing on the tolerability and participant response observed at the maximum tested dose.

Phase 2: Combination Therapy

Research examined the use of the compound alongside an established standard of care, such as muscle relaxants or B vitamins. This stage of research aimed to observe tolerability and examine the observed interaction between the compound and standard of care.

Combination Finding	Outcome
Tolerance Profile	The study reported that the tolerability profile of the combination was generally similar to that of the monotherapy, with no new unexpected adverse events reported in the combined group.
Outcome Measures	Specific research compared various physical function and quality of life scores between the combination group and the standard-of-care-only group. The findings were mixed regarding differential benefit across all measured outcomes.

Common questions about Диклофенак буфус (FAQ)

Q: What types of pain is Диклофенак буфус typically used to treat?

According to the official product information, this medicine is used for the initial treatment of acute inflammatory and painful conditions. This may include flare-ups of certain rheumatic diseases, post-traumatic or post-operative pain, acute attacks of gout, and conditions like renal or biliary colic.

Q: Can the injection site be painful or bruised afterward, and is that normal?

Local pain at the injection site is documented in regulatory sources as a very common side effect. Bruising, which is medically referred to as ecchymosis, is also listed as a less frequent adverse reaction. This local pain is a very common documented reaction.

Q: Does Диклофенак буфус cause drowsiness or make it unsafe to drive?

Official information indicates that this medicine can cause side effects such as dizziness, tiredness, or vision problems. If these occur, regulatory documents advise against driving or operating machinery until the symptoms have completely passed.

Q: Can taking Диклофенак буфус harm my kidneys or liver over time?

Regulatory safety warnings include the potential for adverse effects on the kidney and liver systems. The risk of experiencing serious adverse events is officially stated to increase with the duration of use and dose.

Q: What blood pressure medications should not be used with Диклофенак буфус?

Regulatory documents indicate that Diclofenac may reduce the therapeutic effect of some blood pressure medicines (antihypertensives) and diuretics. Co-administration of these medicines is documented to increase the official risk of renal impairment.

Q: Can people with diabetes use Диклофенак буфус without complications?

Diclofenac is listed in regulatory warnings as requiring careful consideration for patients with risk factors for cardiovascular disease, which includes diabetes mellitus. These patients may be at higher risk for heart- and stroke-related adverse events.

Q: Why is Диклофенак буфус only available as an injection and not a pill?

The solution for injection is used to achieve rapid and predictable systemic delivery of the drug. This fast-acting delivery is often needed for the initial treatment of acute, severe pain before a patient transitions to an oral form of diclofenac, if further treatment is necessary.

Q: Are there any recent research findings on the long-term safety of Diclofenac use?

Regulatory safety warnings are informed by clinical trials of up to three years of duration. These studies indicate that the risk of serious adverse events, including cardiovascular thrombotic events, increases with the duration of use and dose.

Q: What is the difference between Diclofenac potassium and Diclofenac sodium in general?

The difference between the two salt forms is generally related to absorption speed. Diclofenac potassium formulations typically have a faster onset of action because they are designed to be immediate-release, while Diclofenac sodium formulations are often designed for delayed-release.

Q: Is it normal to feel a burning sensation when the injection is administered?

Local pain at the injection site is documented as a very common reaction. The injection technique is intended to minimize local tissue damage and potential complications that can cause severe local reactions, including discomfort.

Q: Are there specific symptoms that mean I should stop using the drug immediately?

Regulatory documents define symptoms of serious adverse reactions as requiring immediate attention. These include signs of bleeding (e.g., black or bloody stools), allergic reaction (e.g., swelling of the face/throat), heart attack/stroke (e.g., chest pain, weakness), or severe skin reactions (e.g., blistering/peeling).

Q: Does Диклофенак буфус affect the central nervous system?

Yes, regulatory documents list adverse effects under the Nervous System category. These include common effects like headache and dizziness, and rare events like convulsions, confusion, and anxiety.

Q: How quickly should I expect to feel pain relief after the injection?

Regulatory information does not specify an exact time for the onset of relief. However, the injectable route is used to achieve a rapid and predictable systemic delivery of the drug for acute pain management.

Q: How long does the effect of a single Диклофенак буфус injection usually last?

According to official pharmacokinetic data, the terminal half-life of the active substance is approximately 2 hours. Clinical information suggests a typical duration of analgesic activity in the range of 4 to 6 hours.

Q: Are there any food or diet restrictions while using Диклофенак буфус?

Regulatory documentation notes specific interactions with alcohol and certain herbal products (like Ginkgo biloba) due to an increased risk of gastrointestinal adverse events. No general food or diet restrictions are typically specified in the regulatory text.

Q: Does this medicine interact with common over-the-counter painkillers like acetaminophen?

Regulatory sources generally indicate no contraindication or known high-risk interaction with paracetamol (acetaminophen). However, co-administration with other NSAIDs (Nonsteroidal Anti-inflammatory Drugs) is restricted.

Q: What are the official guidelines regarding using this drug while breastfeeding?

Official regulatory guidelines state that there are no adequate studies available on the use of this medication during breastfeeding to determine infant risk. Due to limited data, official guidance states that a healthcare provider must assess the potential benefits against the potential risks before recommending use.

Q: Does Диклофенак буфус contain any corticosteroids or steroids?

No. Regulatory documents classify the drug as a Nonsteroidal Anti-inflammatory Drug (NSAID). The active ingredient is solely Diclofenac sodium, which is a compound from the phenylacetic acid class and is not a corticosteroid or steroid.

Q: Can this drug affect the results of lab tests, like liver function tests?

Regulatory documents list the possibility of adverse effects on the liver and kidneys. If these documented serious adverse events were to occur, they would likely be reflected in abnormal results on liver function tests or renal function tests.

Storage and Disposal of Diclofenac Solution for Injection

The storage and disposal requirements for Diclofenac solution for injection are defined by official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Requirement	Condition
Temperature	Do not store above 25°C and do not freeze.
Protection	Store in the original outer carton to protect the solution from light.
Child Safety	Keep out of the sight and reach of children.
Stability	Solution in an opened ampoule is for immediate use only; discard any unused portion immediately.

Official Disposal Instructions

Unused, expired, or leftover medicine must not be thrown away via household rubbish or wastewater. Disposal must follow local regulations for pharmaceutical waste. Used needles, syringes, or broken glass must be placed in a dedicated, puncture-proof sharps container.